...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Human vaccines >Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine
【24h】

Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine

机译：在鼠模型中研究脱细胞百日咳-白喉-破伤风疫苗接种者对原发性白喉-破伤风类毒素加强剂局部反应增强的可能机制

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Acellular pertussis vaccine (aP) in combination with diphtheria (D) and tetanus (T) toxoids (DTaP) was developed successfully in Japan and has been used there since 1981. It has proven to be clinically safe and effective and along with whole-cell pertussis vaccine (wP) combined with D and T toxoids (DTwP) is recommended by WHO for pediatric immunisation. Although the rates of adverse reactions to DTaP are lower than for DTwP, DTaPs have been reported to cause occasional rather severe local reactions to booster doses of D and T combined toxoids (DTd, approximately one-fifth antigen content of the DTaP primary dose) given at 11-12 y of age in Japan. The rates of local reactions increased with each subsequent booster dose of DT based combination vaccines and extensive local redness/ swelling have also been reported for booster doses in DTaP-based schedules in other countries.
机译：脱细胞百日咳疫苗（aP）结合白喉（D）和破伤风（T）类毒素（DTaP）在日本成功开发，自1981年以来已在日本使用。它已被证明在临床上安全有效，并且与全细胞一起使用世卫组织建议将百日咳疫苗（wP）与D和T类毒素（DTwP）组合用于儿科免疫。尽管对DTaP的不良反应发生率低于DTwP，但据报道，DTaP偶尔会给加强剂量的D和T联合类毒素（DTd，约占DTaP主剂量抗原含量的五分之一）引起局部相当严重的局部反应。在日本11至12岁。在随后的其他国家中，基于DTaP的时间表中也报告了局部增强率随DT组合疫苗的每次后续加强剂量而增加，并且已经报道了广泛的局部发红/肿胀。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号